SOD1 and Huntington disease: In 2013, the first phase 1 human trial of an intrathecally delivered ASO, targeting superoxide dismutase 1 (SOD1) in familial amyotrophic lateral sclerosis, was completed without significant safety issues reported, paving the way for such trials with such agents in HD.12